Thalidomide, treat with caution!

Netherlands Journal of Medicine

Volumn 64, Issue 11, 2006, Pages 391-392

  Powell, R J ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BASIC FIBROBLAST GROWTH FACTOR; CORTICOSTEROID; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIODYSPLASIA; ANGIOGENESIS; CACHEXIA; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DROWSINESS; DRUG MECHANISM; DRUG MONITORING; DRUG OVERDOSE; DRUG SAFETY; DRUG USE; EDITORIAL; EPILEPSY; ERYTHEMA NODOSUM LEPROSUM; FATALITY; GENETIC POLYMORPHISM; GENITAL ULCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS VULGARIS; MOUTH ULCER; MULTIPLE MYELOMA; NEUROPATHY; NONHUMAN; PRACTICE GUIDELINE; PYODERMA GANGRENOSUM; SCLERODERMA; T LYMPHOCYTE; TERATOGENICITY;

ADULT; AGED, 80 AND OVER; ANGIODYSPLASIA; ANGIOGENESIS INHIBITORS; CACHEXIA; DRUG DESIGN; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; ORAL ULCER; PYODERMA GANGRENOSUM; TERATOGENS; THALIDOMIDE;

EID: 33845767854     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (8)

1. Koca E, Duman, A, Cetiner D, et al. Successful treatment of myelodysplastic syndrome induced pyoderma gangrenosum. Neth J Med 2006;64:422-4.
2. Heidt J, Langers A, van der Meer F, Brouwer R. Thalidomide as treatment for digestive tract angiodysplasias. Neth J Med 2006;64:425-8.
3. Zeldis JB. Williams BA. Thomas SD. Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999;21(2):319-30.
4. Powell RJ, Gardner-Medwin JM. Guideline for the clinical use and dispensing of Thalidomide. Postgrad Med J 1994;70:901-4.
5. Dmoszynska A, Bojaraska-Junak A, Domanski D, et al. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymph 2002;43:401-6.
6. Neben K, Mytilinoos J, Moehler TM, et al. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 2002;100:2263-5.
7. Vogelsang GB. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-8.
8. Arora M, Wagner JE, Davies SM, et al. Randomised clinical trial of thalidomide, cyclosporine, and prednisolone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001;7:265-73.